generic-eye-drops
16 January 2014Americas

Allergan win bars Sandoz’s Lumigan generic

Drug company Sandoz, the generic arm of Novartis, may not market generic versions of Allergan’s eye drop solution Lumigan before the last patent covering it expires in 2027, a district court decided on January 14.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 March 2026   Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
Americas
12 March 2026   The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.
Americas
12 March 2026   The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.